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Resveratrol therapeutics 
combines both antimicrobial and 
immunomodulatory properties 
against respiratory infection 
by nontypeable Haemophilus 
influenzae
Begoña Euba1,2, Nahikari López-López2, Irene Rodríguez-Arce2, Ariadna Fernández-Calvet2, 
Montserrat Barberán3, Nuria Caturla4, Sara Martí1,5, Roberto Díez-Martínez6 & Junkal 
Garmendia1,2
The respiratory pathogen nontypeable Haemophilus influenzae (NTHi) is an important cause of acute 
exacerbation of chronic obstructive pulmonary disease (AECOPD) that requires efficient treatments. 
A previous screening for host genes differentially expressed upon NTHi infection identified sirtuin-1, 
which encodes a NAD-dependent deacetylase protective against emphysema and is activated by 
resveratrol. This polyphenol concomitantly reduces NTHi viability, therefore highlighting its therapeutic 
potential against NTHi infection at the COPD airway. In this study, resveratrol antimicrobial effect 
on NTHi was shown to be bacteriostatic and did not induce resistance development in vitro. Analysis 
of modulatory properties on the NTHi-host airway epithelial interplay showed that resveratrol 
modulates bacterial invasion but not subcellular location, reduces inflammation without targeting 
phosphodiesterase 4B gene expression, and dampens β defensin-2 gene expression in infected cells. 
Moreover, resveratrol therapeutics against NTHi was evaluated in vivo on mouse respiratory and 
zebrafish septicemia infection model systems, showing to decrease NTHi viability in a dose-dependent 
manner and reduce airway inflammation upon infection, and to have a significant bacterial clearing 
effect without signs of host toxicity, respectively. This study presents resveratrol as a therapeutic of 
particular translational significance due to the attractiveness of targeting both infection and overactive 
inflammation at the COPD airway.
Though typically a commensal of the nasopharynx, the Gram negative bacterium H. influenzae, especially in its 
noncapsulated or nontypeable form (NTHi), is also an opportunistic pathogen causing middle ear infections 
(otitis media), conjunctivitis, community-acquired pneumonia, exacerbations of chronic obstructive pulmonary 
disease (COPD) and, occasionally, invasive disease1,2.
COPD is an airway inflammatory disease characterized by a progressive and not fully reversible airflow 
limitation accompanied by emphysema, fibrosis, chronic overactive inflammation and mucus hypersecretion3. 
COPD is a main leading cause of death, is predicted by the World Health Organization to become the fifth most 
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significant contributor to the worldwide burden of disease by 2020, and it greatly contributes to the economic 
burden of healthcare costs4. Although cigarette smoking is the most common instigating factor in the develop-
ment of COPD, bacterial colonization of these damaged airways may contribute to disease progression, being 
NTHi the most common colonizing bacterium in COPD5. Moreover, the chronic course and evolution of COPD 
is often characterized by periods of symptom exacerbation caused by respiratory pathogens such as NTHi (acute 
exacerbation of COPD, i.e. AECOPD), with a negative impact on the patient’s quality of life and evolution of the 
disease6,7.
Despite the routine therapeutic use of antibiotics, NTHi persists and recurs at the COPD airways, and the 
numbers of antibiotic-resistant strains increase. NTHi is a facultative intracellular pathogen8–16, and subcellular 
location may allow bacterial cells to temporarily evade the immune system and/or antibiotic-based therapeutic 
interventions17,18. Moreover, given its inflammatory properties, common pharmaceuticals used to manage the 
symptoms of COPD include β2-agonists, inhaled corticosteroids and phosphodiesterase 4 (PDE4) inhibitors4,19. 
Of note, NTHi infection is also an inflammatory process, and those pharmaceuticals may influence the infectious 
process20,21, as observed for glucocorticoids such as dexamethasone, which attenuate NTHi-triggered inflam-
mation but may also compromise bacterial clearance in mice22, or for nonbactericidal PDE4 inhibitors such as 
roflumilast N-oxide or rolipram, which dampen NTHi-triggered inflammation23, dampen NTHi intracellular 
invasion and enhance mice lung clearance24, but may also synergize with NTHi to up-regulate PDE4B2 expres-
sion therefore contributing to chemokine induction25. Together, success of current therapeutics is limited due to 
resistance, adverse side effects, tolerance and/or cost4. Therefore, novel treatments being safe, effective and not 
vulnerable to developing resistance are needed to counteract NTHi respiratory infection.
Previous global expression profiling revealed SIRT1, encoding the NAD-dependent deacetylase sirtuin 1, as 
a host cell gene differentially expressed upon NTHi infection24. Emphysema relates to accelerated aging of the 
lungs, and accelerated aging might be due to defective function of endogenous antiaging molecules such as sir-
tuins3. SIRT1 is a negative regulator of matrix metalloproteinase-926 and protects against emphysema27, but its 
expression is reduced in the peripheral lungs of patients with COPD26. Thus, SIRT1 activation may be an attrac-
tive therapeutic approach for COPD28. Of note, the SIRT1 activator resveratrol (3,5,4´-trihydroxystilbene), a nat-
urally occuring polyphenolic phytoalexin produced by a variety of flowering plants in response to unfavourable 
environmental conditions and found in dietary products including peanuts, grapes and red wine, reduces NTHi 
viability24,29. Besides NTHi, resveratrol antimicrobial effect has been shown for several Gram positive and nega-
tive bacteria30–33. Next to its proposed geroprotector role3,28, pathway candidates affected by resveratrol exposure 
in humans are anti-inflammatory mechanisms, cell cycle and programmed cell death pathways, calorie restriction 
mimetic via energy-sensing metabolic regulators, and anti-oxidant properties34. In fact, evidence supports a pro-
tective role of resveratrol in respiratory disease as an anti-inflammatory and antioxidant agent35. Mechanistically, 
resveratrol targets are molecules that bind directly with the polyphenol and whose activity, structure, and/or sta-
bility is altered as a consequence, or molecules whose expression or activity is altered via an indirect mechanism34.
Besides its antimicrobial effect, resveratrol anti-inflammatory action is known to occur during NTHi infec-
tion by suppression of extracellular signal-regulated kinases (ERK)-mediated down-regulation of an alter-
native spliced variant of the adaptor protein myeloid differentiation factor 88 (MyD88) named MyD88 short 
(MyD88s)36. However, both resveratrol antimicrobial and immunomodulatory therapeutic properties have not 
been jointly considered. The existing body of evidence prompted us to hypothesize that resveratrol effectiveness 
for the treatment of NTHi respiratory infection may rely on the combined action of its antimicrobial and host cell 
modulatory effects. Based on this notion, we further analyzed resveratrol antimicrobial properties, its effect on 
bacterial intracellular location and host gene expression in infected cells, and evaluated resveratrol therapeutic 
potential in vivo. Here we show that resveratrol (i) is bacteriostatic and does not induce resistance development 
in NTHi, (ii) reduces NTHi airway epithelial invasion but does not alter its subcellular location, (iii) has an 
anti-inflammatory effect without targeting PDE4B gene expression and dampens human β defensing-2 (hBD2) 
gene expression in NTHi infected airway epithelial cells, (iv) decreases NTHi viability and reduces airway inflam-
mation in lung infected mice, and (v) has a bacterial clearing effect without signs of host toxicity in a newly 
established septicemia model system by zebrafish infection with NTHi. Together, this work presents preclinical 
evidence for resveratrol therapeutic potential against NTHi infection.
Results
Resveratrol effect on NTHi is bacteriostatic and does not induce resistance. Exposure of NTHi 
strain 375, hereafter NTHi375, cells in sBHI to increasing concentrations of resveratrol previously revealed bac-
terial growth inhibition24. Resveratrol has been shown to be bacteriostatic on E. coli and Bacillus subtilis31,32. To 
evaluate if resveratrol is bactericidal or bacteriostatic on NTHi, we incubated pre-grown NTHi375 cells with 
resveratrol 112.5 or 56.25 μg/ml (concentrations selected based on previous observations24), and monitored the 
OD600 and number of viable cells by serial dilution and plating at the indicated time intervals. After 4 h, resveratrol 
112.5 or 56.25 μg/ml-treated cultures showed lower OD600 and number of viable cells than the control untreated 
and vehicle solution ones. Moreover, results of both time and dose dependent assays did not show a reduction 
in OD600 and in the number of viable cells due to resveratrol treatment through time, suggesting it to be bacteri-
ostatic (Fig. 1). We next assessed the ability of NTHi to become resistant to resveratrol through serial passage of 
strain NTHi375 in sBHI broth containing increasing polyphenol concentrations. A range of resveratrol inhibitory 
concentrations consisting of 250, 225, 175, 130, 120 and 112.5 μg/ml were employed. After 15 consecutive over-
night passages, no resistant bacteria were isolated (Fig. S1). In summary, resveratrol is likely to have a bacterio-
static effect on NTHi and, under the conditions tested, it does not induce resistance on strain NTHi375.
Resveratrol has an antimicrobial effect on a panel of NTHi COPD clinical isolates. Genomic 
heterogeneity is a known feature for NTHi37, which may lead to variable resveratrol susceptibility among strains, 
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as shown for other antimicrobials38. To further expand our observations on NTHi375, we evaluated the effect of 
resveratrol on NTHi viability by using a panel of 14 clinical strains isolated from COPD sputum samples render-
ing different typing profiles by PFGE (data not shown). We found that viability decreased for all strains tested in 
a resveratrol dose-dependent manner (Table 1). As observed for NTHi375, bacterial survival was less than 50% at 
a resveratrol concentration of 175 μg/ml; for 5 of the isolates analyzed, bacterial survival was less or equal to 10% 
when incubated with resveratrol 175 μg/ml (Table 1). These results further support resveratrol antimicrobial effect 
on NTHi. Given that NTHi375 has been previously used in host-pathogen interaction studies13–15,24,38, it was next 
used to assess resveratrol modulatory effect on the NTHi-host airway interplay.
Resveratrol efficacy against NTHi infection of cultured airway epithelial cells. In agreement 
with our previous host expression profiling24, NTHi infection increased SIRT1 protein levels in A549 cells. As 
expected, resveratrol addition also increased SIRT1 protein levels, as already seen in uninfected cells; a synergis-
tic effect between NTHi infection and resveratrol addition on SIRT1 protein levels was not observed (Fig. S2). 
Conversely, sirtuin-1 siRNA did not modify NTHi epithelial invasion24, suggesting that SIRT1 expression/activity 
and NTHi cell entry may be uncoupled events.
Resveratrol modulates other molecules within the host cell besides SIRT139. Intracellular cAMP increase has 
been reported to reduce NTHi cell invasion13,24. Given that resveratrol inhibits cAMP-degrading PDEs leading 
to elevated cAMP levels40, host cell treatment with this polyphenol should be likely to reduce bacterial infection. 
However, previous evaluation of resveratrol effect on NTHi airway epithelial infection, performed by A549 cell 
Figure 1. Resveratrol has a bacteriostatic effect on pre-grown NTHi cells. OD600-normalized sBHI cultures 
of NTHi375 were divided into control untreated (circle); resveratrol 112.5 μg/ml (diamond); resveratrol 
56.25 μg/ml (triangle); vehicle solution (square), and incubated for 4 h. At the indicated time points, OD600 was 
recorded (a), and samples were serially diluted and plated on sBHI agar for c.f.u./ml determination (b). After 
4 h, NTHi375 cells treated with both resveratrol 56.25 and 112.5 μg/ml showed a reduction in OD600 and in the 
number of viable cells compared to control untreated (p < 0.0001) and vehicle solution cultures (p < 0.0001 




175 75 25 8.33
P617–9224 35 ± 11 62.8 ± 14.6 87.9 ± 16.9 98.9 ± 2
P621–7028 24.6 ± 15.2 56 ± 8.3 72.6 ± 19.1 80.8 ± 19.4
P636–8296 23.4 ± 6.9 47.5 ± 22.9 79.7 ± 21 95.6 ± 5.5
P642–4396 22.4 ± 4.5 46.2 ± 6.4 56.4 ± 11.5 73 ± 16.5
P595–8370 31.5 ± 15.5 65.8 ± 9.8 86.2 ± 14.8 90 ± 11.5
P615–8618 11 ± 8 40.3 ± 11.7 52.2 ± 16.5 82 ± 18.5
P650–8603 10.8 ± 4.3 50.8 ± 15.4 81.7 ± 18.3 95.5 ± 7.2
P652–8881 4.8 ± 9.5 42.5 ± 18.4 73.7 ± 19.5 88.3 ± 16.4
P662–7189 15 ± 8.4 40 ± 5.9 61.1 ± 11.7 79.2 ± 12.1
P657–8759 23.6 ± 12.3 60 ± 18.9 83.1 ± 16.3 86 ± 14.1
P665–7858 1.1 ± 2.7 70.7 ± 25 90.1 ± 17 88.5 ± 17.5
P669–6977 24 ± 8.9 57.8 ± 9.6 76.7 ± 10.7 89.8 ± 10.4
P672–7661 2.6 ± 3.2 34.3 ± 10.2 87.4 ± 14.5 96.6 ± 6.8
P679–2791 38.4 ± 10.6 62.4 ± 20.3 74.9 ± 17.8 87 ± 13.2
Table 1. Percentage of survival by a panel of 14 NTHi COPD clinical isolates, when incubated with increasing 
concentrations of resveratrol. Values denoted are mean ± SD.
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pre-treatment with resveratrol 20 μM and drug removal before infection, rendered comparable NTHi375 infec-
tion levels for both control and resveratrol pre-treated cells24. Such assays were performed with resveratrol con-
centrations reducing bacterial viability, and drug removal prior to infection was necessary to allow quantifying 
infection rates, which could limit observing a potential resveratrol effect on bacterial location upon infection.
Following this notion, we assessed NTHi adhesion to- and invasion of A549 cells pre-treated with resveratrol 
sub-inhibitory concentrations maintained during bacterial-cell contact. Bacterial adhesion to A549 cells treated 
with increasing resveratrol concentrations (0.75; 1.5; 3 μM) was comparable to that observed for control untreated 
cells (Fig. 2a). Differently, a significant decrease on NTHi375 invasion was observed upon cell treatment with 
resveratrol 3 μM (0.68 μg/ml) (p < 0.05) (Fig. 2b); this resveratrol concentration did not affect NTHi375 bacterial 
or A549 cell viability (data not shown).
Resveratrol penetration into host cells may occur by a passive diffusion mechanism41, and antimicrobial mol-
ecules likely to penetrate epithelial cells can reduce intracellular NTHi viability38. We next asked if resveratrol 
Figure 2. A resveratrol sub-inhibitory concentration lowers NTHi375 invasion of A549 human respiratory 
epithelial cells. Controls (CON): in adhesion and invasion assays (a and b, respectively), cells did not receive 
resveratrol (RESV), but did receive vehicle solution (DMSO) prior and during bacterial contact; in invasion 
assay (c), cells received vehicle solution during gentamicin treatment. Effect of resveratrol sub-inhibitory 
concentrations on NTHi375 adhesion to- (a) and invasion of (b) A549 cells. Cells were pre-treated with 
resveratrol 0.75, 1.5, or 3 μM for 4 h, and the polyphenol was maintained during infection. Bacterial adhesion 
was comparable for resveratrol-treated and control (CON) cells. Mean numbers of NTHi375 entry into cells 
treated with resveratrol 3 μM were significantly lower than those obtained for control (CON) cells (p < 0.05). 
(c) Resveratrol effect on intracellular NTHi375. A549 cells were infected and resveratrol 20 μM was added 
during cell incubation with gentamicin (Gm). Resveratrol did not reduce the number of intracellular bacteria. 
(d) Subcellular location of NTHi375 inside A549 cells shows co-localization with Lamp-1 endosomal marker. 
NTHi was stained with rabbit α-NTHi and Alexa 488-conjugated donkey α-rabbit (green) antibodies. Lamp-1 
was stained with mouse α-Lamp-1 and donkey α-mouse conjugated to RRX (red) antibodies. A549 cells were 
pre-treated with resveratrol 3 μM for 4 h, which was maintained during infection (upper panels); alternatively, 
A549 cells were infected for 2 h and resveratrol 20 μM was added during cell incubation with Gm (lower panels). 
Representative images are shown, taken at 1 h post-Gm. Host cell nuclei location is indicated with dashed lines. 
Bacteria:Lamp-1 co-localization is indicated with arrows.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 12860  | DOI:10.1038/s41598-017-13034-7
could reduce the viability of intracellular bacteria. To do so, A549 cell infection with NTHi375 was performed 
in culture medium without drug supplementation, followed by subsequent incubation in fresh medium supple-
mented with gentamicin to kill extracellular bacteria, and without (CON) or with resveratrol 20 μM. Under these 
conditions, resveratrol did not reduce the number of intracellular bacteria (Fig. 2c). We and others have previ-
ously described that NTHi invades epithelial cells and locates inside a non-proliferative compartment with late 
endosome features10,13–15. In agreement, resveratrol pre-treatment or addition during the gentamicin incubation 
period did not alter such subcellular location (Fig. 2d).
Together, these results show that resveratrol sub-inhibitory concentrations reduce NTHi375 airway epithelial 
cell invasion and, under the conditions tested, this polyphenol does not modify intracellular bacterial numbers 
and/or subcellular location.
Resveratrol modulates NTHi-induced IL-8 and hBD2 expression on A549 airway epithe-
lial cells. Despite previous reports on resveratrol antimicrobial and immunomodulatory properties upon 
NTHi infection24,36, the therapeutic potential of this dual effect has not been jointly considered. Thus, resver-
atrol has been shown to reduce NTHi-induced expression of IL-1β, IL-6, CCL-2 and GM-CSF proinflamma-
tory cytokines in BEAS-2B bronchial epithelial cells36. Separately, IL-8 enhanced expression has been observed 
in NTHi infected A549 cells24. Resveratrol effect on NTHi-induced expression of IL-8 in A549 cells was next 
assessed by cell pre-treatment with resveratrol 20 μM and drug removal before infection, which did not render 
an anti-inflammatory effect at the gene expression or protein secretion levels (Fig. 3b). This lack of effect could 
be related to resveratrol removal prior to infection. To maintain resveratrol at the onset of the infectious inflam-
matory stimulus without jeopardizing bacterial viability, we assessed IL-8 expression and secretion by A549 cells 
incubated with heat killed (HK) bacteria. Under these conditions, IL-8 expression and secretion were stimulated, 
compared to control non-infected cells. Indeed, IL-8 expression/secretion levels were higher in cells incubated 
with HK bacteria than in NTHi infected cells. Moreover, IL-8 gene expression showed a non statistically signifi-
cant but reproducible trend to be lower in resveratrol-treated cells at 2 and 4 h post-incubation with HK bacteria 
(Fig. 3a); likewise, IL-8 protein secretion showed the same decreasing trend in resveratrol-treated cells at 8 h 
post-incubation with HK bacteria (Fig. 3b), compared to control cells receiving vehicle solution.
Resveratrol is known to directly inhibit PDE1, 3 and 4 by competitive inhibition with cAMP in their binding 
sites40. Resveratrol anti-inflammatory effect on NTHi-infected cells may be mediated by MKP-1 phosphatase 
dependent up-regulation of MyD88s expression via a cAMP-PKA-dependent mechanism36. Given that NTHi 
airway epithelial infection stimulates differential expression for several PDEs including PDE4B (the major PDE 
isoform expressed in lung)24, we asked if resveratrol anti-inflammatory effect on NTHi-infected cells could be 
also mediated by modulation of NTHi-induced PDE4B gene expression. PDE4B gene expression was assessed 
in A549 infected cells, in the absence or presence of resveratrol 20 μM. As previously stated, resveratrol removal 
prior- or maintenance during infection was dependent on the use of intact or HK bacteria, respectively. As shown 
in Fig. 3c, PDE4B gene expression was increased in NTHi infected- when compared to control uninfected cells 
(in cells incubated with HK bacteria for 2 and 4 h, p < 0.005 and p < 0.05, respectively). Under these conditions, 
resveratrol treatment did not modify PDE4B gene expression.
Bacteria-induced human β-defensin-2 (hBD2) antimicrobial peptide expression in lung epithelial cells has 
also been shown to be differently modulated by resveratrol42,43. Based on this notion, we investigated whether 
NTHi could induce the expression of hBD2 in A549 cells. hBD2 gene expression was higher in NTHi infected 
than in control uninfected cells (for 1 h infected cells, p = 0.001). Such hBD2 gene expression was lowered to 
control levels upon resveratrol cell pre-treatment (for 1 h infected cells, p < 0.01) (Fig. 3d). HK bacteria did not 
modify hBD2 expression on A549 cells, therefore excluding evaluation of a resveratrol-mediated effect under 
these conditions (data not shown).
These results show that, under the conditions tested, resveratrol anti-inflammatory effect is observed when 
maintained at the onset of the infectious inflammatory stimulus. Resveratrol treatment of NTHi-infected lung 
epithelial cells lowers IL-8 gene expression and protein secretion, hBD2 gene expression, and does not interfere 
PDE4B gene expression.
Antimicrobial and anti-inflammatory effects of resveratrol administration on mouse pulmo-
nary infection with NTHi. Next, we sought to determine the impact of resveratrol oral administration in 
vivo by using a mouse model system of NTHi respiratory infection. We used two regimens of oral resveratrol (100 
or 150 mg/kg) consisting of three administrations prior to infection (48, 24, 1 h before infection) and three admin-
istrations at 6, 12 and 18 h post-infection (hpi). Fewer NTHi375 bacteria were recovered at 12 hpi from lung and 
BALF samples of mice treated with resveratrol 150 mg/kg than from mice receiving vehicle solution (for lung, 
p < 0.01; for BALF, p = 0.01), or receiving resveratrol 100 mg/kg (for lung, p = 0.01; for BALF, p < 0.05) (Fig. 4a,b). 
Bacterial loads on lung and BALF samples were comparable for resveratrol 100 mg/kg-treated and untreated 
infected mice. No differences in terms of bacterial counts were observed at 24 hpi among the three conditions 
tested. Treatment with resveratrol has been shown before to decrease NTHi-induced expression of IL-1β and IL-6 
in mice lung tissue36. In this study, analysis of NTHi-induced expression of KC and TNF-α pro-inflammatory 
mediators in mice lung tissue euthanized at 12 hpi rendered higher numbers than those obtained for control 
non-infected animals (for KC and TNF-α, p = 0.01); moreover, treatment with resveratrol 150 mg/kg decreased 
NTHi-induced expression of KC and TNF-α in infected mice lung tissue at 12 hpi (for KC, p < 0.01; for TNF-α, 
p < 0.05) (Fig. 4c,d). No differences in terms of KC and TNF-α expression were observed in resveratrol treated 
and control untreated non-infected animals.
Microscopy score of average histopathological lesions in samples from mice infected with NTHi375 was also 
determined along the respiratory tract and compared for untreated and resveratrol 150 mg/kg-treated mice, euth-
anized at 12 hpi. Overall comparison of scored lesions in the lower airways of NTHi infected mice showed lower 
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inflammatory reaction scores for resveratrol-treated mice. This reduction was significant for PMNs at the bronchi 
and alveoli in infected mice treated with resveratrol, compared to control untreated mice (p = 0.01) (Table 2). As 
an exception, the upper airways of resveratrol-treated infected mice showed a significant increase for PMNs at the 
nasal cavity compared to control untreated animals (p < 0.05) (Table 2).
In sum, these results show that resveratrol 150 mg/kg reduces bacterial load and whole-lung inflammatory 
markers such as KC and TNF-α. This is in turn reflected by lower PMN in the broncho-alveolar space.
Resveratrol has an antimicrobial protective effect on zebrafish infection with NTHi. Zebrafish 
has been used for over a decade to study the mechanisms of a variety of inflammatory disorders and infectious 
diseases. Zebrafish presents adaptive immunity 4–6 weeks after birth, when it becomes a suitable model to analyze 
novel antimicrobial agents44. Thus, aiming to validate the in vivo data shown above in an alternative animal model 
of infection, we tested H. influenzae infection on adult zebrafish by bacterial intraperitoneal injection45,46. The 
infection dose was first optimized by injection of 6 animal groups (n = 10) with 10 μl of a NTHi375 suspension 
containing 5 × 105, 5 × 106, 5 × 107, 5 × 108 or 5 × 109 c.f.u./ml, or saline solution 0.9% as a control. NTHi375 
severely reduced zebrafish survival. An infection dose consisting of ∼5 × 107 c.f.u./zebrafish caused progressive 
Figure 3. Resveratrol modulates NTHi-induced A549 cell gene expression. Controls (CON): non-infected cells. 
A549 cells were treated with resveratrol (RESV) 20 μM or DMSO for 4 h, removed prior to bacterial addition 
(NTHi), or maintained when HK bacteria were used as an inflammatory stimulus (NTHi HK). To monitor gene 
expression, bacteria were added for 1, 2 or 4 h. Relative quantity (RQ) of human IL-8 (2−ΔCt × 100) (a), PDE4B 
(2−ΔCt × 100) (c), and hBD2 (2−ΔCt × 1000000) (d) mRNA were measured by qRT-PCR. (b) Quantification of 
IL-8 protein secretion by A549 cells, measured by ELISA at 8 h post-infection (hpi). NTHi375 induced IL-8 
expression in A549 cells, being significant at 1 (for HK stimulated cells, p < 0.0005), 2 (for NTHi and HK 
stimulated cells, p < 0.01 and p < 0.0001, respectively) and 4 hpi (for NTHi and HK stimulated cells, p < 0.005 
and p < 0.0001, respectively). IL-8 expression was higher in A549 cells incubated with HK bacteria than in 
NTHi infected cells (for 4 hpi, p < 0.05). NTHi375 induced PDE4B expression in A549 cells, being significant at 
2 and 4 hpi (for HK incubated cells, p < 0.005 and p < 0.05, respectively). NTHi375 induced hBD2 expression 
at 1 hpi (p = 0.001). NTHi triggered IL-8 secretion by A549 cells at 8 hpi (for NTHi and HK stimulated 
cells, p < 0.0005). IL-8 secretion was higher in cells incubated with HK bacteria than in NTHi infected cells 
(p < 0.05). Under these conditions, resveratrol shows a trend to reduce IL-8 gene expression and protein 
secretion, and lowers hBD2 gene expression (p < 0.01). White bars correspond to non-infected (CON) or to 
NTHi infected cells (NTHi); gray bars correspond to cells stimulated with HK bacteria (NTHi HK).
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death of the animals after injection (data not shown), therefore presenting a novel preclinical sepsis model system 
suitable for further use.
Before performing a resveratrol protective assay in adult zebrafish, a resveratrol acute toxicity assay was 
carried out in zebrafish embryos following the OECD TG 236 “Fish embryo acute toxicity (FET) test”. Results 
showed that resveratrol was not toxic, being 1 mg/ml the highest dose tested (data not shown). Next, we assessed 
resveratrol antimicrobial effect on NTHi375 infected zebrafish by using a therapeutic regimen of intraperitoneal 
resveratrol (0.1 mg/g) consisting of two administrations at 29 and 53 hpi. Survival rate for resveratrol-treated and 
control untreated groups was monitored up to 5 days post-infection. Mortality rate in resveratrol-treated infected 
zebrafish was significantly lower than in control animals receiving vehicle solution (p < 0.0001); indeed, survival 
was similar for infected zebrafish receiving resveratrol than for control non-infected animals (Fig. 5a). To quantify 
resveratrol protective effect, we determined the number of bacterial c.f.u. by collecting blood from the caudal fin 
of NTHi infected zebrafish at 1 and 2 days post-challenge, corresponding to 5 h before- and 19 h post-resveratrol 
treatment. Significantly fewer NTHi375 bacteria were recovered at 19 h post-treatment from zebrafish treated 
with resveratrol than from those receiving perfusion solution-DMSO (1:1) (p < 0.0001) (Fig. 5b).
Altogether, these results present zebrafish as a preclinical sepsis model system useful for in vivo therapeutic 
evaluation against NTHi infection. By using this system, we observed both significant resveratrol-mediated NTHi 
clearing effect upon zebrafish infection and subsequent increased survival.
Figure 4. Effect of resveratrol administration on bacterial loads and pro-inflammatory markers in CD1 mice 
infected by NTHi. Mice were infected intranasally with ∼108 bacteria/mouse. Resveratrol (100 or 150 mg/kg/
dose) was administered orally (RESV100 or RESV150). Controls: animals were administered vehicle solution 
but did not receive resveratrol. Bacterial counts were determined at 12 and 24 hpi for lungs (log10 c.f.u./lung) 
(a) and BALF (log10 c.f.u./ml BALF) samples (b). At 12 hpi, NTHi375 counts were significantly lower in mice 
treated with resveratrol 150 mg/kg (triangle) than in control mice treated with vehicle solution (circle) (for 
lung, p < 0.01; for BALF, p = 0.01), and than in mice treated with resveratrol 100 mg/kg (square) (for lung, 
p = 0.01; for BALF, p < 0.05). Relative quantities of mouse KC (2−ΔCt × 100) (c) and TNF-α (2−ΔCt × 100) (d) 
mRNA were measured by RT-qPCR analysis on lung samples corresponding to non-infected untreated, non-
infected resveratrol 150 mg/kg treated, NTHi375 infected untreated, and NTHi375 infected resveratrol 150 mg/
kg treated groups. At 12 hpi, KC and TNF-α gene expression was increased in infected compared to non-
infected mice (for KC and TNF-α, p = 0.01). Both KC and TNF-α gene expression was lower in NTHi infected 
resveratrol treated- than in untreated mice (for KC, p < 0.01, for TNF-α, p < 0.05).
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Discussion
This study delineates the effect of resveratrol administration on infection by NTHi. By using conditions mimick-
ing therapeutic resveratrol administration in vitro, in cultured respiratory epithelial cells and in vivo, we estab-
lished the impact of this natural polyphenol on a number of properties related to NTHi viability, host-pathogen 
interplay and progression of infection. Given that NTHi is largely associated with COPD chronic infection and 
AECOPD frequency47, therapeutics targeting both infection and overactive inflammation at the COPD airway 
are of particular interest. Preventive and therapeutic benefits of this antimicrobial/anti-inflammatory duality 
have been exploited for the macrolide antibiotic azithromycin. Thus, clinical studies suggest that azithromycin 
long-term low-dose use to prevent and/or manage chronic inflammatory airway disorders such as AECOPD may 
be beneficial, but could also increase the rate of macrolide resistance by colonising opportunistic pathogens. In 
fact, adverse effects of long-term azithromycin use in patients with chronic lung diseases have been suggested48, 
and its use for AECOPD prevention is under debate. Following this notion, this study assessed resveratrol ther-
apeutic potential against NTHi infection, which may also rely on its antimicrobial/anti-inflammatory duality. 
Previous work has been separately performed on resveratrol antibacterial and anti-inflammatory activities against 
NTHi infection24,36. This is, to our knowledge, the first study jointly considering the therapeutic benefits of both 
















NTHi375 Control untreated 1.7 ± 0.4 1.6 ± 0.2 1 ± 0.2 1.4 ± 0.2 0.2 ± 0.2 0.5 ± 0 0.7 ± 0.1 0.9 ± 0.1
NTHi375 RESV150 1 ± 0.3 c2.5 ± 0.2 0.8 ± 0.1 1 ± 0.2 0.1 ± 0.1 0.5 ± 0 0.8 ± 0.1 d0.3 ± 0.1
Table 2. Score of histopathological lesions found in the airways of untreated or resveratrol treated mice, 
intranasally infected with NTHi375. aControl untreated animals were administered vehicle solution 
(PBS:DMSO, 1:1). RESV treated animals were administered three RESV doses (150 mg/kg) at 48, 24, and 
1 h before infection and one RESV (150 mg/kg) dose at 6 hpi. Mice were euthanized at 12 hpi. bStatistical 
comparisons of mean values were performed using the two-tail t test. cLarger numbers of PMNs in the upper 
airways lumen of RESV treated than control untreated animals (p < 0.05) infected by NTHi375. dLower PMNs 
numbers at the bronchi and alveoli of mice treated with RESV, compared to controls (p =0.01) infected by 
NTHi375.
Figure 5. Effect of resveratrol administration on zebrafish infected by NTHi. Zebrafish were infected 
intraperitoneally with ∼5×107 bacteria/individual. When necessary, resveratrol 0.1 mg/g/dose (RESV0.1) was 
administered intraperitoneally at 29 and 53 hpi. (a) Effect of resveratrol administration on adult zebrafish 
survival upon NTHi375 infection. Non-infected groups were administered perfusion solution-DMSO (1:1) 
(triangle) or saline solution 0.9% (diamond); infected groups were administered perfusion solution-DMSO 
(1:1) (circle) or resveratrol (square). Survival rate is reported as percentage (mean ± SD) of adult individuals 
survival at 120 hpi. Survival of NTHi infected zebrafish was significantly higher in resveratrol treated- and 
in untreated animals (p < 0.0001). (b) Bacterial counts on zebrafish blood samples from the caudal fin were 
determined at 24 and 48 hpi (log10 c.f.u./ml blood), corresponding to 5 h before- and 19 h post-resveratrol 
treatment, respectively. At 48 hpi, NTHi375 counts were lower in resveratrol treated (square) than in control 
vehicle administered (circle) zebrafish (p < 0.0001). Perfusion solution-DMSO (1:1) was used as vehicle 
solution.
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properties. Thus, our use of in vitro and in vivo model systems has allowed establishing associations between 
resveratrol effects, doses, bacterial inhibitory concentrations and antimicrobial/host modulatory properties.
Resveratrol has demonstrated antibacterial activity against several Gram-negative and Gram-positive bac-
terial pathogens30–33,49,50. Mechanistically, it is thought to work by inhibiting bacterial ATP synthase51, and by 
site-specific oxidative damage to the bacterial cell, resulting in a bacteriostatic effect31,32. Our results show that 
resveratrol is likely to be bacteriostatic on NTHi, it has a comparable effect on a whole range of genomically 
unrelated NTHi clinical isolates, and resistance is not induced in vitro; as a counterpoint to these likely beneficial 
therapeutic properties, and different to macrolides38,52, resveratrol does not seem to reduce NTHi intracellular 
numbers despite using working concentrations shown to reduce viability for the infecting strain.
At the cellular level, our results indicate that each experimental setting is crucial to properly address resvera-
trol effects during infection. Thus, resveratrol concentrations inhibiting NTHi viability or being sub-inhibitory 
determine drug removal prior to- or drug maintenance during infection, respectively. Of note, although evalu-
ation of resveratrol impact on the NTHi-airway epithelia interface by cell pre-treatment with a resveratrol bac-
tericidal concentration did not modify NTHi invasion rate24, a maintained sub-inhibitory dose is able to lower 
NTHi epithelial invasion. We speculate that resveratrol effects could be transitory and/or reversible, and this 
aspect should be further elucidated and taken into consideration when designing any administration regimen. 
Consequently, this notion may also apply when assessing resveratrol immunomodulatory effects on infected cells. 
Resveratrol has been shown to suppress the inflammatory response of host cells infected by several bacterial path-
ogens including Porphyromonas gingivalis and Streptococcus pneumoniae43,53, and also to reduce inflammation 
on NTHi-infected cells36; of note, such observation did not consider resveratrol antimicrobial effect therefore 
maintaining the polyphenol upon cell infection with NTHi strain 12. In practical terms, the use of HK bacteria is 
likely to mimic the inflammatory stimulus and allow assessing resveratrol immunomodulatory properties on cells 
infected by susceptible pathogens without jeopardizing their viability. This approach previously allowed address-
ing resveratrol-based suppression of inflammatory responses on P. gingivalis infected human gingival epithelia53, 
and has been used in the present study, showing a trend to reduce IL-8 expression in NTHi HK infected human 
airway epithelial cells. Resveratrol also modulates positive or negatively antimicrobial peptide (AMP) expression 
in cells infected by S. pneumoniae or Pseudomonas aeruginosa, respectively42,43. NTHi has been shown to induce 
AMP expression in primary bronchial epithelial cells54, and we show here that resveratrol reduces hBD2 expres-
sion on A549 cells infected by NTHi. In addition, resveratrol has anti-oxidant properties in cultured epithelial 
cells infected by respiratory pathogens inducing oxidative stress, such as S. pneumoniae and P. aeruginosa42,55. 
NTHi has been shown to induce lung oxidative stress mainly in phagocytic cells56; however, we could not detect 
this stress in infected cultured epithelia (data not shown), therefore excluding the possibility of assessing a poten-
tial resveratrol antioxidant effect on NTHi infected cells. Given that oxidative stress is intimately associated to 
COPD progression and exacerbation, therapeutic intervention with antioxidants may have a beneficial outcome 
in the treatment of COPD57.
Future work will tackle alternative host cell infection model systems to monitor resveratrol antioxidant prop-
erties upon NTHi infection.
Resveratrol effectiveness has been shown by reducing bacterial loads in lungs and BALF samples during NTHi 
mouse respiratory infection, with a clearing effect dependent on resveratrol dose. Resveratrol antimicrobial 
potential has been previously proven in rat and mouse models infected by Serratia marcescens or respiratory 
syncytial virus, respectively58,59. In this study, we further support resveratrol antimicrobial effect by presenting 
a newly established preclinical sepsis model system by NTHi zebrafish infection. Moreover, testing resveratrol 
toxicity in zebrafish supports previous evidences for its low cytotoxicity in human cells33. Besides its antibacterial 
effect, evidence suggests that resveratrol has anti-inflammatory properties in vivo59,60. This is also the case in the 
lungs of NTHi infected mice36. Our results revealed parallel bacterial clearance and reduction of inflammation in 
resveratrol treated NTHi infected lungs. Of note, the upper airways of resveratrol-treated infected mice showed 
increased PMN numbers at the nasal cavity compared to untreated animals, which could somehow contribute 
to reduce bacterial load and inflammation at the lower airway, even though the reasons for such increase are 
currently unknown. Likewise, we acknowledge that the observed suppression of lung inflammation could be not 
only due to resveratrol anti-inflammatory properties, but also to its bacterial clearing effect, actively reducing the 
inflammatory stimulus by lowering bacterial viability. Importantly, this aspect should be taken into consideration 
when analyzing and concluding on potential immunomodulatory properties by antimicrobial therapeutic agents. 
The use of anti-inflammatory therapeutics against NTHi respiratory infection has been previously tested in vivo 
for dexamethasone, azithromycin and the non-bactericidal PDE4 inhibitors roflumilast N-oxide and rolipram, 
highlighting the benefits of PDE4 inhibition22–24,38. Resveratrol is known to inhibit PDE4, but our PDE4B expres-
sion data did not show a resveratrol inhibitory effect at the gene expression level, leading us to speculate that it 
may occur by competitive inhibition with cAMP, as previously stated40.
Overall, plant polyphenols are important components of human diet, and a number of them are considered to 
possess chemopreventive and therapeutic properties. Numerous dietary plants contain polyphenols, resveratrol 
belonging to the non-flavonoid family. Although no studies have specifically examined resveratrol concentrations 
in relation to respiratory disease risk, a number of epidemiologic studies identified that consumption of various 
antioxidant-rich foods, many of which known to contain resveratrol, are protective against asthma outcomes35. 
Resveratrol-driven inflammatory reduction in COPD28,61–63 and its potential to slow aging-related deterioration 
of lung function and structure by maintaining alveolar cell integrity64, support a resveratrol protective role against 
chronic airway disease. The present study sheds light on resveratrol as an attractive therapy that timely combines 
anti-inflammatory and antimicrobial properties, therefore targeting both infection and overactive inflammation 
at the COPD airway. Future research will consider the efficacy and toxicity of resveratrol when present in the 
human airways, and explore the therapeutic potential of other plant polyphenols against respiratory infection.
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Methods
Bacterial strains, media, growth conditions, interfering drugs. NTHi strains were grown at 37 °C, 
5% CO2 on chocolate agar (Biomérieux) or on brain heart infusion (BHI) agar supplemented with 10 μg/ml 
hemin and 10 μg/ml nicotinamide adenine dinucleotide (NAD), referred to as sBHI. NTHi liquid cultures were 
grown in sBHI. When necessary, heat killed (HK) bacteria were used; for this purpose, a bacterial suspension 
recovered with 1 ml PBS from a freshly grown chocolate agar plate was adjusted to OD600 = 1 (∼109 c.f.u./ml) and 
incubated at 80 °C for 30 min. NTHi375 is a genome sequenced clinical isolate previously used in host-pathogen 
interplay studies13,15,65,66. NTHi clinical strains shown Table 1 were isolated from COPD sputum samples during 
independent AECOPD episodes at Bellvitge University Hospital, Spain. Strain relatedness was determined by 
pulse field gel electrophoresis (PFGE)67. Resveratrol was purchased from Sigma-Aldrich, and was also kindly 
supplied by Monteloeder (Elche, Spain). Resveratrol (20 mM, i.e. 4.56 mg/ml) stock solutions were prepared in 
dimethyl sulfoxide (DMSO) and diluted to the required working concentrations in Earle’s balanced salt solution 
(EBSS; Gibco), sBHI or PBS, depending on the assay type (see below).
Resveratrol susceptibility assays. NTHi susceptibility to resveratrol was assessed as described before24. 
To assess if resveratrol effect on NTHi is bactericidal or bacteriostatic, bacteria grown on chocolate agar for 16 h 
were inoculated (2 to 5 colonies) in 20 ml sBHI and incubated for 11 h under shaking. Cultures were then diluted 
in 100 ml sBHI to OD600 = 0.05, incubated with agitation to OD600 = 0.5 and divided into 4 flasks (20 ml/flask) as 
it follows: (i) control untreated; (ii) resveratrol 112.5 μg/ml; (iii) resveratrol 56.25 μg/ml; (iv) DMSO, by adding a 
volume identical to that used in (ii). Cultures were incubated with agitation for 4 h. When indicated, OD600 was 
recorded and culture samples were serially diluted and plated on sBHI agar. Data are shown as OD600 and c.f.u./
ml. Experiments were performed in duplicate at least four times (n > 8).
NTHi serial passage in the presence of resveratrol. Bacteria grown on chocolate agar for 16 h were 
inoculated (1 colony) in 3 ml sBHI and incubated for 11 h under shaking; starting inocula were prepared in 
quadruplicate (cultures 1 to 4, CL1 to CL4). Resveratrol 20 mM stock solution was diluted in sBHI (250; 225; 175; 
130; 120; 112.5 μg/ml). One hundred μl of each resveratrol dilution were transferred to individual wells in 96-well 
microtiter plates; a vehicle solution control consisting of a DMSO volume equivalent to that used for the highest 
resveratrol concentration tested was performed in parallel. The assay was initiated by inoculating 1 μl of the 
previously grown bacterial cultures in each well, and further incubation for 24 h at 37 °C shaking. Cultures were 
then passaged (10 μl in 100 μl fresh sBHI with resveratrol or vehicle solution) every day for 15 days. At various 
time points throughout the cycling, culture samples were serially diluted and plated on sBHI agar. The assay was 
performed in duplicate (n > 8).
Infection of cultured epithelial cells. Carcinomic human alveolar basal epithelial cells (A549, ATTC 
CCL-185) were maintained, and NTHi infected to quantify bacterial adhesion and invasion, as described pre-
viously15. When indicated, cells were pre-treated with resveratrol (0.75; 1.5; 3 μM) or vehicle solution (DMSO) 
for 4 h in 1 ml EBSS, and drug exposure was maintained during bacterium-cell contact. Alternatively, cells were 
infected, and resveratrol 20 μM or DMSO was added during the gentamicin incubation period. These treatments 
did not induce A549 cytotoxicity, verified by measuring the release of lactate dehydrogenase and by micros-
copy (data not shown). Controls (CON) were performed by using a DMSO volume corresponding to that of 
the highest resveratrol concentration tested in each assay. Results are expressed as c.f.u./well. Experiments were 
performed in triplicate and at least in three independent occasions (n ≥ 9).
Immunofluorescence microscopy. A549 cells were seeded on 13 mm circular coverslips in 24-well tissue 
culture plates and NTHi infected for 2 h as previously described15. Infected cells were incubated in RPMI 1640 
containing 10% FCS, Hepes 10 mM and gentamicin 200 μg/ml for 1 h. When necessary, cells were pre-treated 
with resveratrol 3 μM or DMSO for 4 h in 1 ml EBSS, maintained during bacterium-cell contact; alternatively, 
cells were infected, and resveratrol 20 μM or DMSO was added during the gentamicin incubation period. Cells 
were washed three times with PBS and fixed with 3.7% paraformaldehyde (PFA) in PBS pH 7.4 for 15 min at 
room temperature. Bacteria were stained with rabbit anti-NTHi serum15 diluted 1:600. Late endosomes were 
stained with mouse monoclonal anti-human Lamp-1 H4A3 antibody (Developmental Studies Hybridoma Bank) 
diluted 1:70. Donkey anti-rabbit conjugated to Alexa 488 and donkey anti-mouse conjugated to Rhodamine 
Red-X (RRX) secondary antibodies (Jackson Immunological) were diluted 1:100. Samples were analyzed with 
a Carl Zeiss Axioskop 2 plus fluorescence microscope and a Carl Zeiss Axio Cam MRm monochrome camera.
RNA extraction and real-time quantitative PCR. A549 cells were seeded on 24-well tissue culture 
plates, and infected for 1, 2 or 4 h in EBSS. When indicated, cells were pre-treated with resveratrol 20 μM or 
DMSO for 4 h in 1 ml EBSS, and removed prior to bacterial addition. Alternatively, cells were pre-treated with 
resveratrol 20 μM or DMSO for 4 h in 1 ml EBSS, and a suspension containing HK bacteria (equivalent in num-
bers to that of the infecting dose) was added for 1, 2 or 4 h, without removal of resveratrol or DMSO. Following 
treatment and/or NTHi stimulation, total RNA was isolated from A549 cells using a Nucleospin RNAII kit 
(Macherey-Nagel) as recommended by the manufacturer and including an on column DNase treatment step. 
When necessary, total RNA was isolated from mouse lungs using TRIzol reagent (Invitrogen). Total RNA qual-
ity was evaluated using RNA 6000 Nano LabChips (Agilent 2100 Bioanalyzer, Santa Clara, CA). All samples 
had intact 18 S and 28 S ribosomal RNA bands with RNA integrity numbers (RIN) between 9.3 to 10. Reverse 
transcription was performed using 1 μg of RNA by PrimerScript RT Reagent kit (Takara). To amplify human 
il-8, pde4b, and mouse kc, tnf-α, gapdh genes, 6 ng of cDNA were used; to amplify human hbd2, 50 ng of cDNA 
were used as template. In all cases, 20 μl reaction mixtures containing 1X SYBR Premix Ex Taq II (Tli RNaseH 
Plus) (Takara) and the adequate primer mix were used. When necessary, human gapdh was amplified using 6 
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or 50 ng of cDNA as template. Fluorescence data were analyzed with AriaMx Real-Time PCR System (Agilent 
Technologies). The comparative threshold cycle (Ct) method was used to obtain relative quantities of mRNAs 
that were normalized using human or mouse gapdh as an endogenous control. Intron-spanning primers were 
designed with Primer-BLAST software (NCBI)24,68 (Table S1). All measures were performed in triplicate and at 
least four times (n > 12).
Western Blot. A549 cells were seeded before each experiment on 6-well tissue culture plates at 2.8 × 106 cells 
per well. Cells were pre-treated with resveratrol 20 μM for 4 h in 4 ml EBSS per well, and then infected for 10, 20, 
30, 50, 70, 90, 100 or 120 min with NTHi375. Next, wells were washed 3 times with cold PBS, scrapped and lysed 
with 100 μl of lysis buffer (62.5 mM Tris-HCl pH 6.8, 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% w/v bromo-
phenol blue) on ice. Samples were sonicated, boiled at 100 °C for 10 min and cooled on ice before 10% SDS-PAGE 
and western blotting. SIRT1 was detected with primary rabbit anti-SIRT1 antibody (sc-15404, Santa Cruz 
Biotechnology) diluted 1:1,000; tubulin, used as a loading control, was detected with primary mouse anti-tubulin 
antibody (Sigma-Aldrich) diluted 1:3,000. Secondary goat anti-rabbit IgG and anti-mouse IgG (whole mole-
cule, Sigma-Aldrich) antibodies, conjugated to horseradish peroxidase, were diluted 1:1,000. ECL AdvanceTM 
Western Blotting Detection Kit (GE HealthCare) was used for detection. Western blots were performed at least 
three times by using independently generated A549 cell extracts. Densitometry analysis on scanned images was 
performed using ImageJ software (http://rsb.info.nih.gov/ij/download.html). Bands in each lane were analyzed 
using the label peaks tool, and the mean intensity was recorded. Results are expressed as relative level of protein 
(mean intensity of protein SIRT1/mean intensity of tubulin).
Secretion of IL-8. A549 cells were maintained, seeded on 24-well tissue culture plates, and infected for 2 h. 
When necessary, cells were pre-treated with resveratrol 20 μM or DMSO for 4 h in 1 ml EBSS, and removed prior 
to bacterial addition. Alternatively, cells were pre-treated with resveratrol 20 μM or DMSO for 4 h in 1 ml EBSS, 
and a suspension containing HK bacteria was added for 2 h, without removal of resveratrol or DMSO. Cells were 
washed 3 times with PBS and incubated for 6 h in RPMI 1640 containing 10% FCS, Hepes 10 mM, gentamicin 
100 μg/ml, and resveratrol 20 μM or DMSO. Supernatants were collected from the wells, cell debris was removed 
by centrifugation and samples were frozen at −80 °C until use. IL-8 levels in the supernatants were measured by 
ELISA (Abnova KA0115) with sensitivity <2 pg/ml. Results are expressed as IL-8 pg/ml. Infections were per-
formed in duplicate and at least twice (n > 4).
NTHi mouse lung infection. A previously described mouse model of NTHi respiratory infec-
tion was used24,38,67,69,70 at the Institute of Agrobiotechnology facilities (registration number ES/31–2016–
000002-CR-SU-US). Animal handling and procedures were in accordance with the current European (Directive 
86/609/EEC) and National (Real Decreto 53/2013) legislations, following the FELASA and ARRIVE guidelines, 
and with the approval of the Universidad Pública de Navarra (UPNa) Animal Experimentation Committee 
(Comité de Ética, Experimentación Animal y Bioseguridad) and the local Government authorization. Resveratrol 
treatment was performed at doses of 100 or 150 mg/kg of body weight in 0.1 ml PBS-DMSO (1:1) and adminis-
tered by oroesophageal gavage (Popper&Sons Inc.). Administrations were performed at 48, 24, 1 h before infec-
tion and at 6, 12 and 18 h post-infection (hpi) (resveratrol administrations at 12 and 18 hpi were performed in 
mice euthanized at 24 hpi). NTHi375 was used for lung infection, and mice were randomly divided into 6 infected 
(n = 6) and 2 control non-infected (n = 3) groups: (i) treated with 100 mg/kg resveratrol, euthanized at 12 hpi; (ii) 
treated with 100 mg/kg resveratrol, euthanized at 24 hpi; (iii) treated with 150 mg/kg resveratrol, euthanized at 12 
hpi; (iv) treated with 150 mg/kg resveratrol, euthanized at 24 hpi; (v) treated with vehicle solution (PBS-DMSO, 
1:1), euthanized at 12 hpi; (vi) treated with vehicle solution, euthanized at 24 hpi; (vii) control, administered 
150 mg/kg resveratrol; (viii) control, administered vehicle solution. For NTHi intranasal infection, 20 μl of a 
NTHi375 suspension containing ∼5 × 109 c.f.u./ml (1 × 108 c.f.u./mouse) was placed at the entrance of the nos-
trils until complete inhalation by the mouse, previously anesthetized (ketamine-xylazine, 3:1). At 12- or 24 hpi, 
mice were euthanized and lungs were aseptically removed. The left lung was individually weighed in sterile bags 
(Stomacher80, Seward Medical) and homogenized 1:10 (wt/vol) in PBS. Each homogenate was serially 10-fold 
diluted in PBS and plated in triplicate on sBHI agar to determine the number of viable bacteria. Results are shown 
as log10 c.f.u./lung. The right lung was fixed in 10% neutral buffered formalin. Heads and necks, containing upper 
airways, larynxes, and tracheas, were fixed in the same buffered formalin for histology. In parallel, BALF samples 
were obtained by perfusion and collection of 0.7 ml of PBS, with the help of a sterile 20 G (1.1-mm diameter) 
Vialon intravenous catheter (Becton-Dickinson) inserted into the trachea. Each recovered BALF fraction was 
serially 10-fold diluted and plated on sBHI agar as described above. Results are shown as log10 c.f.u./ml BALF.
Histopathology and lesions score was performed as it follows. Heads and necks were rinsed in running tap 
water for 1 h, immersed in 5% nitric acid for 24–36 h until complete decalcification, and 7–8 transaxial slices were 
made every 3–4 mm beginning at the nostrils and finishing in the caudal tracheas. Transaxial slices and lungs 
were embedded in paraffin, and 4- to 6 μm sections were stained with hematoxylin and eosin (H&E) by standard 
procedures, and examined by microscopy to determine the presence and extent of inflammatory lesions. Sections 
were examined blind as sets by a trained veterinary pathologist (Dr. M. Barberán). Parameters characterizing an 
acute inflammatory reaction in upper airways and lung, including hemorrhages, hyperemia, polymorphonuclear 
cell infiltrates (PMNs) and alveolar macrophages, were subjectively scored on a scale of 0 to 3 (0: absent, 1: mild, 2: 
moderate, 3: severe). For tissue control, similar organs obtained from non-infected control and resveratrol treated 
mice were processed in an identical manner to the infected tissues. Images were observed and digitalized using an 
Olympus Vanox AHBS3 microscope coupled to an Olympus DP12 digital camera.
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NTHi adult zebrafish infection. Animal experiments conducted at The Zebrafish Lab (http://www.the-
zebrafishlab.com) animal housing facility were performed according to EU guidelines (http://ec.europa.eu/
environment/chemicals/lab_animals/home_en.htm), and the approval of the Universidad de Navarra (UNAV) 
Ethics Committee for Animal Experimentation (Protocol 03417). Once lack of resveratrol toxicity in zebraf-
ish was confirmed (data not shown), adult zebrafish (n = 10 per group) were randomly divided into 2 infected 
and 2 non-infected groups. Infected groups were injected with 10 μl of a NTHi375 suspension containing 
∼5 × 109 c.f.u./ml, i.e. ∼5 × 107 c.f.u./zebrafish, prepared in perfusion solution (Grifols, Spain). At 29 and 53 hpi, 
an infected group was intraperitoneally administered resveratrol at a dosis of 0.1 mg/g of body weight in 10 μl of 
perfusion solution-DMSO (1:1); the other groups were administered perfusion solution-DMSO (1:1) or saline 
solution 0.9% as a control. Survival rate for each group was monitored three times per day during 5 days after 
infection. To quantify resveratrol protective effect, the numbers of bacterial c.f.u. in blood samples collected from 
zebrafish caudal fin were quantified at 24 and 48 hpi, i.e. 5 h before- and 19 h post-treatment. Each recovered 
blood fraction was serially 10-fold diluted in PBS and spread on BHI agar to determine the number of viable 
bacteria. Results are shown as log10 c.f.u./ml blood.
Statistical analysis. For bacterial viability, cell infection, gene expression, IL-8 secretion and bacterial loads 
in lungs and BALF samples, mean±SD were calculated and statistical comparisons of means were performed 
using the two-tail Student’s t test. For zebrafish assays, statistical analysis were performed by using the two-tailed 
Student’s t test (for two groups), analysis of variance (ANOVA) was chosen for multiple comparisons, and the 
log-rank (Mantel–Cox) and Gehan–Breslow–Wilcoxon tests were used to draw, analyze and compare survival 
curves. In all cases, a p < 0.05 value was considered statistically significant. Analyses were performed using the 
Prism software, version 7 for Mac (GraphPad Software) statistical package.
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